Acute respiratory failure (ARF) is defined as a condition in which the patient's arterial oxygen pressure (PaO2) is less than 60 mmHg and/or arterial carbon dioxide pressure (PaCO2) is more than 45 mmHg. This result occurs when the weakness of the respiratory system leads to the inability to transfer oxygen from the air to the blood or to remove carbon dioxide from the blood and transfer it to the surrounding air, and various mechanisms such as hypoventilation, diffusion disorder, shunt, ventila
Conditions
Interventions
Intervention 1: Intervention group: This group will receive daily 5000 international units of vitamin D in the form of oral drops (5 cc oral drops) and 2000 mg of vitamin C intravenously in the serum.
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: hospitalized patients in the intensive care unit suffering from acute respiratory failure (PaO2 = 60 mmHg or PaCO2 > 45 mmHg) not Suffering from a nervous system disease that prevents the patient from being separated from the mechanical ventilation device not suffering from AIDS not suffering from Liver failure not Suffering from kidney diseases including nephrotic syndrome- not suffering from gout not being Pregnancy and breastfeeding Vitamin D level below 50 ng/mL not suffering from hypercalcemia (total calcium > 10.6 mg/dL) not Suffering from hyperphosphatemia (> 1.45 mmol/liter) not suffering from Tuberculosis not suffering from sarcoidosis not Passing more than 24 hours from the diagnosis of the disease to the time of entering the study not participating in other interventional studies in the last 30 days not consuming vitamin D and vitamin C supplements in the last 30 days
Exclusion criteria
Exclusion criteria: Death or hospitalization of the patient less than 3 days from the start of the intervention Unwillingness to continue studying and cooperating in it developing contraindications for the administration of vitamin D and vitamin C according to the opinion of the attending physician at the time of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interlukin6. Timepoint: The results are evaluated at the beginning of the study and at the end of the 10th da. Method of measurement: The level of interlukin6 in serum is with ELISA method. | — |
Secondary
| Measure | Time frame |
|---|---|
| The duration of connection to the ventilator. Timepoint: the end of the study. Method of measurement: From the patient's file.;The duration of connection to the ventilator. Timepoint: 28th and 90th day of study. Method of measurement: From the patient's file. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Vafa
Iran University of Medical Sciences
Outcome results
None listed